CJC 1295 DAC 5 mg Research Profile

Current catalog abstract

Documented material overview

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) designed to stimulate endogenous growth hormone (GH) secretion through activation of GHRH receptors in the anterior pituitary. The incorporation of the DAC modification allows the peptide to bind to serum albumin, significantly extending its half-life and enabling sustained release and prolonged biological activity compared to non-modified GHRH analogs. This extended activity results in increased pulsatile secretion of growth hormone and subsequent elevation of insulin-like growth factor-1 (IGF-1) levels over an extended period. In research settings, CJC-1295 with DAC has been studied for its role in endocrine regulation, growth hormone dynamics, tissue repair processes, and metabolic function. Its structure is engineered for enhanced stability and resistance to enzymatic degradation, making it a valuable compound for investigating long-acting growth hormone modulation pathways. This product is intended strictly for research purposes only and is not for human consumption, clinical use, or therapeutic application.